The immune system and cancer

Transplant-type immunity mediated by T-lymphocytes and cytokines (positive effect of IL-2, interferons and TNFα and β) may be involved in anti-tumor immunity. In addition, NK cells and LAK cells (killer-activated lymphokines) are involved in the anti-tumor response. NK cells have a toxic effect on tumor cells without prior sensitization. They may be the first natural defense system in the early stages of tumor growth. Tumor tissue is infiltrated by a functionally modified population of T-ly, the so-called tumor infiltrating lymphocytes (TIL), which, after isolation, in vitro multiplication and infusion into the body by infusion, specifically kill tumor cells by cytotoxic effects. .

The differences in the phenotype of normal and tumor cells in the expression of not only membrane antigens are called changes in the antigenic equipment of tumor cells.

Qualitative changes
Neoantigens

The formation of neoantigens is conditioned by mutations in other, physiological antigens. These are recognized as foreign and an immune response is initiated against them and the cells that carry them. The new antigens may be specific for each type of tumor. They are then referred to as tumor-specific transplant antigens (TSTA)''. ''Transplant-type neo-antigens have the ability to elicit an immune response leading to the destruction of transformed cells at the beginning of the malignant process. Leakage of transformed cells by immune control mechanisms can be caused by selection in a population of tumor cells or immunosuppression individuals. Immunological activity depends on the age and condition of the individual. Immunosuppression can also be caused by chemical, physical and chemical factors. TSTA expression depends on the etiology of cell transformation, it is variable. The expression of TSTA in tumors induced by both chemical carcinogens and radiation is dependent on latency (from encounter with the carcinogen to onset of tumor growth). Tumors of viral etiology caused by the same virus carry the same TSTA. Such TSTAs can lead to immunization of the body. The immune system is then able to destroy the transformed cells. Cytotoxic T cells play a major role in rejection.
 * An example of the regulation of tumor growth by the immune system is Burkitt's lymphoma - tumor-transformed B-lymphocytes are removed by immunological mechanisms with the crucial involvement of T-ly. On their surface, they recognize virus-induced TSTA presented by molecules HLA class I. In the absence or suppression of T-cells, tumor growth develops rapidly.

The immune response directed against TSTA is important in the spontaneous destruction of tumor cells at the beginning of the malignant process.
 * Prevention: vaccination in endemic areas,
 * therapy: immunization against neoantigens.

Quantitative changes
The expression of antigens that normally occur on healthy cells can be increased or decreased to zero in tumors. They may also be antigens that do not occur in healthy, fully differentiated cells. These are often antigens normally present in embryogenesis. Quantitatively altered antigen expression in tumor cells may be an important diagnostic marker. These antigenic markers are either bound to the cell surface (MHC class I and II antigens) or are secreted into the bloodstream from tumor cells. Determination of serum carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) levels is used to improve the diagnosis and control of cancer treatment.
 * Elevated CEA levels are characteristic of GIT tumors. However, it is not just a specific marker of tumor growth. Elevated levels have also been reported in other non-cancerous GIT disease processes. In normal cells, its expression is organ-limited and time-limited. In fetuses, it is found in the & nbsp; tissue of the intestine, pancreas and liver. In adults, it is found in low amounts in the intestinal mucosa, lungs and lactating mammary glands.
 * Alpha-fetoprotein is present in the fetal liver, fetal serum, and low levels are found in the serum of healthy adults. In adults, elevated serum levels are often associated with hepatoma or testicular teratoma.


 * MHC antigens are also used to monitor the course of certain cancers and the effectiveness of treatment. Decreased expression of class I antigens correlates with the aggressiveness and invasiveness of the gastric, ovarian, colon, kidney, breast and pancreatic tumors. The expression of class I antigens in tumor tissue is determined using β-2-microglobulin. Determination of the expression of MHC class II antigens is important for prognosis, especially in leukemia, where their absence in the leukemia cell membrane means a worse prognosis.

Other antigenic determinants used for diagnosis, prognosis, and treatment are differentiation antigens ( membrane CD traits). They can be used to refine the diagnosis of morphologically indistinguishable cancers, especially hematological malignancies and lymphomas, and subsequently to choose treatment procedures.

Used literature

 * ŠTERZL, Ivan, et al. Základy imunologie. 1. vydání. Praha : Karolinum, 2005.  ISBN 978-80-246-0972-0.